Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases

Haematologica

Volumn 91, Issue 11, 2006, Pages 1465-1472

  Leibundgut, Elisabeth Oppliger ^a   Horn, Michael Peter ^a   Brunold, Claudio ^a   Pfanner Meyer, Brigitte ^a   Marti, Dorothee ^a   Hirsiger, Hans ^a   Tobler, Andreas ^a   Zwicky, Caroline ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Endothelial; Hemangioblasts; Myeloproliferative diseases; PCR; Progenitor cells; Trafficking

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CLONOGENIC ASSAY; CONTROLLED STUDY; ERYTHROCYTOSIS; FEMALE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; STEM CELL; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ENDOTHELIAL CELLS; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PROTEIN TRANSPORT; STEM CELLS;

EID: 33750940761     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Andreasson B, Swolin B, Kutti J. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2000;64:188-93.
2. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001;98:3249-55.
3. Passamonti F, Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L, et al. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica 2003;88:1123-9.
4. Oppliger Leibundgut E, Brunold C, Marti D, Horn MP, Seiler C, Schroeder V, et al. Progenitor cell trafficking in physiologic conditions and in myeloproliferative diseases: quantification of CD34+ cells by polymerase chain reaction. Haematologica 2005;90:875-80.
5. Eichmann A, Corbel C, Nataf V, Vaigot P, Breant C, Le Douarin NM. Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci USA 1997;94:5141-6.
6. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
7. Pelosi E, Valteiri M, Coppola S, Botta R, Gabbianelli M, Lulli V, et al. Identification of the hemangioblast in postnatal life. Blood 2002;100:3203-8.
8. Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G, et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:5688-95.
9. Elsheikh E, Uzunel M, He Z, Holgersson J, Nowak G, Sumitran-Holgersson S. Only a specific subset of numan peripheral-blood monocytes has endothelial-like functional capacity. Blood 2005;106:2347-55.
10. Glod J, Kobiler D, Noel M, Koneru R, Lehrer S, Medina D, et al. Monocytes form a vascular barrier and participate in vessel repair after brain injury. Blood 2006;107:940-6.
11. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al., GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
12. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
13. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-75.
14. Zwicky C, Theiler L, Zbaren K, Ischi E, Tobler A. The predictive value of clonogenic stem cell assays for the diagnosis of polycythaemia vera. Br J Haematol 2002;117:598-604.
15. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
16. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
17. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005;128:42-8.
18. Bergamaschi G, Pramparo T, Rosti V, Ramajoli I, Gregato G, Massa M, et al. Clonal origin of circulating endothelial progenitor cells in patients with myelofibrosis with myeloid metaplasma. Blood 2004;104:667a[Abstract].
19. Rosti V, Bergamaschi G, Pramparo T, Massa M, Ramajoli I, Gregato G, et al. Circulating endothelial progenitor cells are clonal in patients with myelofibrosis with myeloid metaplasia. Congress of the EHA 2005;656[Abstract].